HerAnova Lifesciences has raised $13.5M in seed funding, a round that underscores growing investor appetite for women’s health innovation. The biotech company, founded in 2022, is focused on non-invasive diagnostics and treatments for endometriosis and infertility, areas long underserved by traditional medical research.
With operations in both the United States and Asia, HerAnova is backed by a team of serial entrepreneurs and seasoned multinational executives, supported by a scientific advisory board. The fresh capital arrives as the company looks to advance its pipeline, though specific use-of-funds details were not disclosed. The round’s size, notable for a seed stage, signals confidence in its approach to tackling conditions that affect millions of women worldwide.
